Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway

Executive Summary

Accelerated approval would help agency monitor gene therapies for durability and off-target effects, US FDA commissioner says.

You may also be interested in...



FDA’s Gottlieb Says His Departure Won’t Stop Forward Progress On Key Initiatives

Outgoing commissioner say he has 'extreme confidence' in soon-to-be-acting Commissioner Ned Sharpless and other agency leaders, and expects initiatives advanced during his tenure will be ‘encapsulated and enshrined in regulation and policy’ because they are built on a solid administrative record.

Rx Spending Growth To Be Driven By New Drug Entries, CMS Says

Advances in cancer, diabetes, and Alzheimer's could lead to expensive new treatments, contributing to spending increases in next decade, according to CMS projections.

Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers

FDA continues to emphasize the routine and the positive, even though strains on staff and sponsors increase as shutdown grinds on. CBER's new clinical reviewers would oversee the clinical investigation, development and review of cell and gene therapies, although a timeline on the hiring is unclear.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel